Flagship merges a portfolio pair for 'immuno-microbiome,' to reach clinic next year

Wall Street bull

Flagship Ventures plans to create a new immune-microbiome company that will have a candidate in the clinic next year--through the combination of a pair of its existing portfolio companies. The resulting company has nabbed $40 million thus far and is moving forward with a combined employee staff of 42.

The merger is of Evelo Biosciences and Epiva Biosciences--two companies founded by Flagship’s VentureLabs back in 2014. The resulting company will be known as Evelo Biosciences and will be headed up by president and CEO Simba Gill, who ran the prior iteration of Evelo. Flagship’s Noubar Afeyan is the chairman of the combined company.

“Each company, through its proprietary screening platform, identified bacteria which both up-regulate and down-regulate the immune system in human in vitro systems,” Afeyan told FierceBiotech. “Those same bacteria, in some cases, show efficacy in in vivo systems, and those are potential candidates that we are moving forward into human testing.”

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

He added: “This is strategic move, enabling the focus of resources to accelerate and broaden the work of both companies to discover and advance novel therapies, build partnerships and deliver treatments to patients.”

Evelo is the first company to work to systematically identify, characterize and understand the biology of cancer-associated bacteria and bacterial immune activators. Its work is expected to offer a better perspective on tumor metabolism and immuno-oncology.

For its part, Epiva was working on treating conditions involving inflammation and aberrant immune responses by modulating the microbiome. It was developing bacterial therapeutics aimed at restoring a more normal microbiome, like that found in healthy people.

“Evelo was focused on the microbiome for immune system activation in oncology, while Epiva was investigating the microbiome to down-regulate the immune system for allergy, autoimmunity and inflammatory diseases,” Afeyan told FierceBiotech. “Working independently for the past few years, both companies came to a similar conclusion: the immune system and the microbiome interact to form a single metasystem, the immuno-microbiome.”

- check out the release

Related Articles:
Flagship launches another microbiome biotech with $35M and a focus on cancer
White House launches $121M-plus microbiome research initiative
Flagship banks $537M to back the next batch of biotechs

Read more on

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.